# EDGAR Filing Document

**Accession Number:** 0001014763
**File Stem:** 0001493152-25-017508
**Filing Date:** 2025-10
**Character Count:** 11301
**Document Hash:** e7f2ee5f84e292d20cb98da55bf7363f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017508.hdr.sgml**: 20251009

**ACCESSION NUMBER**: 0001493152-25-017508

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251009

**DATE AS OF CHANGE**: 20251009

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ainos, Inc.
- **CENTRAL INDEX KEY:** 0001014763
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 751974352
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-46755
- **FILM NUMBER:** 251383534

**BUSINESS ADDRESS:**
- **STREET 1:** AINOS, INC.
- **STREET 2:** 8880 RIO SAN DIEGO DRIVE SUITE 800
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108
- **BUSINESS PHONE:** 858-869-2986

**MAIL ADDRESS:**
- **STREET 1:** AINOS, INC.
- **STREET 2:** 8880 RIO SAN DIEGO DRIVE SUITE 800
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARILLO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 19960516
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AINOS INC
- **CENTRAL INDEX KEY:** 0001859309

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 8880 RIO SAN DIEGO DRIVE
- **STREET 2:** SUITE 800
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108
- **BUSINESS PHONE:** 213005220

**MAIL ADDRESS:**
- **STREET 1:** 8880 RIO SAN DIEGO DRIVE
- **STREET 2:** SUITE 800
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 12)**

**Ainos, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**00902F402**

*(CUSIP Number)*

**Chun-Hsien Tsai**<br>14F.,No. 61, Sec. 4, New Taipei Bouleva,<br>Xinzhuang District<br>New Taipei City 242 F5 F5<br>886-37-581999

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/06/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00902F402** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ainos Inc.** | Name of reporting person<br>**Ainos Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3253854.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**491263.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**491263.00** | Aggregate amount beneficially owned by each reporting person<br>**491263.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.13%** | Percent of class represented by amount in Row (11)<br>**9.13%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The number of securities in Row 7 includes, after giving effect to the one-for-five reverse stock split of the Issuer's common stock effected on June 30, 2025 (the "June 2025 Reverse Split"), (i) 491,263 shares of common stock, $0.01 par value, of Ainos, Inc., a Texas corporation (the "Issuer"), owned directly by Ainos Inc., a Cayman Islands company ("Ainos KY"), (ii) 933,958 shares pursuant to a Voting Agreement dated January 26, 2024 (the "2024 Voting Agreement"), by and among the Reporting Person, and Chun-Hsien Tsai, Ting Chuan Lee, Chun-Jung Tsai, and Chung-Yi Tsai (the "Tsai Group"); (iii) 100,500 shares of common stock pursuant to a Voting Agreement dated March 7, 2024 (the "2024 Voting Agreement II") with Chih-Heng Lu; (iv) 635,652 shares pursuant to a Voting Agreement dated May 3, 2024 between Ainos KY and ASE Test, Inc. ("ASE Test" and the "ASE Voting Agreement") (with the 635,652 ASE Test shares consisting of the following (a) 11,777 shares owned by ASE Test, (b) 99,875 shares issuable to ASE Test upon conversion of outstanding convertible notes of the Issuer (c) 424,000 shares issuable to ASE Test upon conversion of a convertible note of the Issuer issuable within 60 days), and (d) 100,000 shares issuable to ASE Test upon exercise of warrants to purchase 100,000 shares of the Issuer with ASE Test, (v) 1,037,206 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation ("TCNT Voting Agreement"), and (vi) 55,275 shares pursuant to a Voting Agreement dated March 10, 2025 between Ainos KY and Hsin-Liang Lee (the "2025 Voting Agreement"). The numbers in Rows 9, 11 and 13 represents beneficial ownership of 491,263 shares of common stock of the Issuer, consisting of 491,263 shares owned directly by Ainos KY and excludes (i) 933,958 shares pursuant to the 2024 Voting Agreement; (ii) 100,500 shares of common stock pursuant to the 2024 Voting Agreement II; (iii) 635,652 shares pursuant to the ASE Voting Agreement, (iv) 1,037,206 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation, and (v) 55,275 shares pursuant to the 2025 Voting Agreement. The percentage in Row 13 is based on the sum of, after giving effect to the June 2025 Reverse Split, (i) 4,759,021 shares of Common Stock outstanding as of September 5, 2025 as set forth in the prospectus supplement of the Issuer filed with the SEC on September 5, 2025, 2025 and (ii) 623,875 total shares issuable to ASE Test upon conversion of outstanding convertible note and exercisable warrant of the Issuer. This Amendment No. 12 to Schedule 13D ("Amendment No. 11") amends and supplements the Schedule 13D dated April 28, 2021 (the "Original Statement"), as amended and restated by Amendment No. 1 dated December 13, 2023, as amended by Amendment No. 2 dated March 8, 2022, Amendment No. 3 dated September 2, 2022, Amendment No. 4 dated August 15, 2023, Amendment No. 5 dated January 29, 2024, Amendment No. 6 dated March 11, 2024, Amendment No. 7 dated May 6, 2024, Amendment No.8 dated August 20, 2024, Amendment No.9 dated November 26, 2024, Amendment No.10 dated March 12, 2025, and Amendment No. 11 dated April 9, 2025 (the Original Statement, as so amended shall be known as the "Statement"), with respect to the Common Stock of the Issuer. Unless otherwise indicated, all capitalized terms used herein shall have the same meaning as set forth in the Statement. Except as set forth below, there are no changes to the information set forth in the Statement. Items 2, 3, 4, 5 and 6 of the Statement are hereby amended as follows:

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Ainos, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO, CA, 92108

**Item 4. Purpose of Transaction**

Ainos KY acquired the Common stock in the Issuer for investment purposes.

TCNT sold the 62,794 shares of the issuer's common stock for general operating purposes.

Except as disclosed herein, each of the parties has no plans which relate to or would result in an event described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, each of the Parties may, from time to time, engage in discussions, whether initiated by the Parties or another party, concerning proposals for transactions or other arrangements that may relate to or, if consummated, result in an event described in Item 4 of Schedule 13D. Each of the Parties may review and evaluate their respective investments in the Issuer at any time, whether in light of the discussions described in the immediately preceding sentence or otherwise, which may give rise to plans or proposals that, if consummated, would result in one or more of the events described in Item 4 of Schedule 13D. Any such discussion or actions may consider various factors, including, without limitation, the Issuer's business prospects and other developments concerning the Issuer, alternative investment opportunities, general economic conditions, financial and stock market conditions and any other facts and circumstances that may become known to the Parties regarding or related to the matters described in this Statement.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5 of the Statement are hereby amended and restated as follows:

(a) - (b) The information requested by these paragraphs are incorporated herein by reference to the cover pages to this Amendment No. 11.

**(b)**
—

**(c)**
Since the most recent filing of Amendment No. 11 to Schedule 13D on April 9, 2025, the following transactions have occurred:

(1) On June 30, 2025, the Issuer effected an one-for-five reverse stock split of its common stock.

(2) From June 25, 2025 through October 6, 2025, TCNT sold a total of 62,794 shares of the issuer's common stock, which are subject to the TCNT Voting Agreement.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Other than voting agreements discussed herein and previously, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among Ainos KY or the parties and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ainos Inc.

**Signature:** /s/ Chun-Hsien Tsai

**Name/Title:** Chun-Hsien Tsai/Director and CEO

**Date:** 10/09/2025